Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure

Circulation: Heart Failure

Volumn 2, Issue 6, 2009, Pages 532-540

  Rademaker, Miriam T ^a   Charles, Christopher J ^a   Nicholls, M Gary ^a   Richards, A Mark ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Diuretics; Heart failure; Hemodynamics; Hormones; Renal function; Urocortin 2

Indexed keywords

ALDOSTERONE; FUROSEMIDE; NATRIURETIC FACTOR; RENIN; UROCORTIN II; VASOPRESSIN;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIURESIS; FEMALE; HEART FAILURE; HEART LEFT ATRIUM PRESSURE; HEART OUTPUT; KIDNEY FUNCTION; MEAN ARTERIAL PRESSURE; NATRIURESIS; NONHUMAN; PLASMA RENIN ACTIVITY; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; SODIUM URINE LEVEL; URINE VOLUME; VASCULAR RESISTANCE; VASOPRESSIN BLOOD LEVEL;

ALDOSTERONE; ANIMALS; BIOLOGICAL MARKERS; CARDIAC PACING, ARTIFICIAL; CARDIOVASCULAR AGENTS; CORTICOTROPIN-RELEASING HORMONE; CREATININE; DISEASE MODELS, ANIMAL; DIURETICS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FUROSEMIDE; HEART FAILURE; HEMODYNAMICS; INFUSIONS, INTRA-ARTERIAL; KIDNEY; MICE; NATRIURESIS; POTASSIUM; RENIN; RENIN-ANGIOTENSIN SYSTEM; SHEEP; TIME FACTORS; URINATION; UROCORTINS; VASOPRESSINS;

EID: 77952521665     PISSN: 19413289     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.109.861336     Document Type: Article

References (37)

1. Hsu SY, Hsueh AJ. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med. 2001;7:605-611.
2. Wiley KE, Davenport AP. CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br J Pharmacol. 2004;143:508-514.
3. Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, Rivier J, Chien KR, Vale WW, Peterson KL. The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Nat Acad Sci USA. 2004;101:3697-3702.
4. Rademaker MT, Cameron VA, Charles CJ, Richards AM. Integrated hemodynamic, hormonal and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation. 2005;112: 3624-3632.
5. Davis ME, Pemberton CJ, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM, Rademaker MT, Richards AM. Urocortin 2 infusion in healthy humans hemodynamic, neurohormonal, and renal responses. J Am Coll Cardiol. 2007;49:461-471.
6. Davis ME, Pemberton CJ, Yandle TG, Fisher SS, Lainchbury JG, Frampton CM, Rademaker MT, Richards AM. Urocortin 2 infusion in human heart failure. Eur Heart J. 2007;28:2589-2597.
7. Liu CN, Yang C, Liu XY, Li S. In vivo protective effects of urocortin on ischemia-reperfusion injury in rat heart via free radical mechanisms. Can J Physiol Pharmacol. 2005;83:459-465.
8. Wang DJ, Gottlieb SS. Diuretics: still the mainstay of treatment. Crit Care Med. 2008;36:S89-S94.
9. Francis GS. Acute decompensated heart failure: the cardiorenal syndrome. Cleve Clin J Med. 2006;73:S8-S136.
10. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203-210.
11. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001;96:132-143.
12. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759-1764.
13. Neuberg GW, Miller AB, O'Connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Nye RG, Pressler ML, Wertheimer JH, Packer M; PRAISE Investigators. Prospective Randomized Amlodipine Survival Evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2001;144:31-38.
14. Weber KT. Furosemide in the long-term management of heart failure: the good, the bad, and the uncertain. J Am Coll Cardiol. 2004;44:1308-1310.
15. Krum H, Cameron P. Diuretics in the treatment of heart failure: mainstay of therapy or potential hazard? J Card Fail. 2006;12:333-335.
16. Fitzpatrick MA, Nicholls MG, Espiner EA, Ikram H, Bagshaw P, Yandle TG. Neurohumoral changes during the onset and offset of ovine heart failure: role of ANP. Am J Physiol Heart Circ Physiol. 1989;256: H1052-H1059.
17. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Nicholls MG, Richards AM. Natriuretic peptide responses to acute and chronic pacing in sheep. Am J Physiol Heart Circ Physiol. 1996;270:H594-H602.
18. Rademaker MT, Charles CJ, Nicholls MG, Richards AM. Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure. Clin Sci (Lond). 2007;114:635-642.
19. Rademaker MT, Fitzpatrick MA, Charles CJ, Richards AM, Nicholls MG, Espiner EA, Sybertz E. Comparison of chronic neutral endopeptidase inhibition and furosemide in an ovine model of heart failure. J Cardiovasc Pharmacol. 1996;27:439-446.
20. Rademaker MT, Charles CJ, Richards AM. Urocortin 1 administration from the onset of rapid left ventricular pacing represses progression to overt heart failure. Am J Physiol Heart Circ Physiol. 2007;293: H1536-H1544.
21. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61-67.
22. Gardiner SM, March JE, Kemp PA, Davenport AP, Wiley KE, Bennett T. Regional hemodynamic actions of selective corticotropin-releasing factor type 2 receptor ligands in conscious rats. J Pharmacol Exp Ther. 2005; 312:53-60.
23. Rademaker MT, Charles CJ, Espiner EA, Fisher S, Frampton CM, Kirkpatrick CM, Lainchbury JG, Nicholls MG, Richards AM, Vale WW. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J Am Coll Cardiol. 2002;40:1495-1505.
24. Goebel JA, Van Bakel AB. Rational use of diuretics in acute decompensated heart failure. Curr Heart Fail Rep. 2008;5:153-162.
25. Ikram H, Chan W, Espiner EA, Nicholls MG. Haemodynamic and hormone responses to acute and chronic furosemide therapy in congestive heart failure. Clin Sci (Lond). 1980;59:443-449.
26. Cohn JN. Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system. Adv Ther. 2007;24:1290-1304.
27. Sica DA, Gehr TW. Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet. 1996;30:229-249.
28. Ikeda K, Tojo K, Otsubo C, Udagawa T, Hosoya T, Tajima N, Nakao K, Kawamura M. Effects of urocortin II on neonatal rat cardiac myocytes and non-myocytes. Peptides. 2005;26:2473-2481.
29. Robertson GL. Physiology of vasopressin, oxytocin, and thirst. In: Kenneth Becker, ed. Principles and Practice of Endocrinology and Metabolism. 3 rd ed. Chapter 25. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:276-285.
30. Dormans TP, Pickkers P, Russel FG, Smits P. Vascular effects of loop diuretics. Cardiovasc Res. 1996;32:988-997.
31. Pickkers P, Dormans TP, Russel FG, Hughes AD, Thien T, Schaper N, Smits P. Direct vascular effects of furosemide in humans. Circulation. 1997;96:1847-1852.
32. Abdelrahman AM, Lin Lim S, Pang CC. Influence of urocortin and corticotropin releasing factor on venous tone in conscious rats. Eur J Pharmacol. 2005;510:107-111.
33. Dieterle T, Belke DD, Hoshijima M, Chien KR, Bale T, Vale WW, Dillmann WH, Perterson KL. Urocortin II improves calcium handling and contractility in isolated cardiac myocytes from wild-type and muscle LIM protein knock-out mice. Circulation. 2003;108(suppl IV):341.
34. Scarabelli TM, Pasini E, Stephanou A, Comini L, Curello S, Raddino R, Ferrari R, Knight R, Latchman DS. Urocortin promotes hemodynamic and bioenergetic recovery and improves cell survival in the isolated rat heart exposed to ischemia/reperfusion. J Am Coll Cardiol. 2002;40: 155-161.
35. Yao X, He GW, Chan FL, Lau CW, Tsang SY, Chen ZY, Huang Y. Endothelium-dependent and-independent coronary relaxation induced by urocortin. J Card Surg. 2002;17:347-349.
36. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Lainchbury JG, Richards AM. Endogenous urocortins reduce vascular tone and renin-aldosterone/ endothelin activity in experimental heart failure. Eur Heart J. 2005;26:2046-2054.
37. Chae JI, Ju SK, Lee MK, Park JH, Yoon JH, Shim JH, Lee DS. cDNA cloning and analysis of tissue-specific gene expression of rat urocortin II. Mol Biol (Mosk). 2009;43:82-87.